Health Trials

IBI363 + Chemotherapy

2

Review clinical trials related to IBI363 + Chemotherapy. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Perioprative Study of IBI363 in Patients With MHC-II-Negative Locally Advanced Gastric Cancer

This is a phase 2 study designed to evaluate the safety and efficacy of IBI363 in combination with oxaliplatin and capecitabine (XELOX) or S-1 and oxaliplatin (SOX) in perioprative treatment of locally advanced MHC-II-negative gastric and gastroesophageal junction adenocarcinoma.

Participants needed: 60
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Zhejiang Cancer HospitalUpdated: Jan 8, 2026Locations: 1
Eligibility criteria

Patients voluntarily enrolled in this study and signed informed consent forms; [+9]

Pregnant or lactating women, or women planning to become pregnant within 6 month... [+8]

Read more
Status: Recruiting

Study of IBI363 in Patients with Advanced First-line Gastric Cancer

This is a phase 1b study designed to evaluate the safety, tolerability and efficacy of IBI363 in combination with oxaliplatin and capecitabine (XELOX) in first-line treatment of unresectable advanced or metastatic gastric and gastroesophageal junction adenocarcinoma.

Participants needed: 40
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Xiangdong ChengUpdated: Nov 20, 2024Locations: 1
Eligibility criteria

Male or female subjects, ≥ 18 years and ≤75 years. [+4]

Women who are pregnant or lactating, or intending to become pregnant before, dur... [+2]

Read more